

November 3, 2014

Mandatory Exchange & Termination

IBS Group Holding Limited

Reg S DR CUSIP: 450939103

Reg S DR ISIN: US 4509391037

DR Ticker Symbol: IBSG (Frankfurt Stock Exchange)

Ratio (DRs: Underlying Shares): 1:1

BNY Mellon has been notified that IBS Group Holding Limited (“IBS Group Holding”) shareholders have approved a reorganization of IBS Group Holding by way of a Scheme of Arrangement where IBS Group Holding DRs will be exchanged for new Luxoft Holding Inc (“Luxoft”) shares. As a result, all IBS Group Holding DRs held as of October 31, 2014, the Scheme Record Date, will be exchanged on a mandatory basis at the rate of 0.95 new Luxoft shares for every 1 IBS Group Holding DR held. The new Luxoft shares are expected to be delivered to the depositary on November 7, 2014, the Scheme Effective Date. Holders of IBS Group Holding DRs in Euroclear and Clearstream will receive their new Luxoft share entitlement in Euroclear and Clearstream’s respective DTC Participant accounts.

Effective November 7, 2014, IBS Group Holding DR holders are required on a mandatory basis to surrender their DRs to BNY Mellon for cancellation and exchange for the new Luxoft Holding, Inc. shares. Upon the surrender and cancellation of all outstanding DRs following the Effective Date, the IBS Group Holding DR facility will be terminated.

The books have been closed for all transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Ravi Davis

Vice President

+1 212 815-2267

Adrdesk@bnymellon.com

London

Damon Rowan

Vice President

+44 207 964 6527

damon.rowan@bnymellon.com

Hong Kong

Herston Powers

Vice President

+852 2 840 9868

Herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliates and dealers. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities.